Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

  • - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile